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Body of article 
 
Modulation of co-inhibitory and co-stimulatory immune checkpoint pathway 
activity with antibody-based therapies has emerged as a promising anti-
cancer strategy. Although responses to such agents are limited to a modest 
fraction of treated patients, those deriving benefit have the potential for 
durable remissions and possibly even cure [1-8]. The identification of 
biomarkers predictive of response and resistance to such therapies therefore 
remains an area of high scientific priority.  
 
In humans, adoptive transfer of tumour-infiltrating lymphocytes (TILs) with 
concomitant administration of interleukin-2 (IL-2) mediates tumour regression 
in 34-40% of patients with advanced melanoma [9]. Efforts have been focused 
for some time on the characterisation of antigens recognised by TILs. 
Melanoma TILs have been demonstrated to recognise shared antigens on 
melanoma cell lines established from different patients, in a class I major-
histocompatibility complex (MHC)-restricted manner in vitro [10,11]. The first 
gene identified to code for an antigen recognised on human tumours by 
autologous TILs was MAGE-1, silent in normal tissues except in testes, and 
expressed by a number of other solid tumour subtypes [12]. Subsequently, 
three further self-proteins, all melanoma/melanocyte lineage-specific, 
encoded by MART-1, tyrosinase and gp100, were identified [13-15]. Although 
these ‘public’ tumour-associated antigens appeared attractive targets for both 
adoptive cell-based and vaccination strategies, neither approach was 
observed to yield particularly promising activity in the clinical setting [reviewed 
in 16].  
 
The identification of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a 
co-inhibitory immune checkpoint molecule, followed by the demonstration of 
efficient rejection of established murine tumours with CTLA-4 ‘blockade’, 
highlighted immune regulation as a potential contributor to the limited clinical 
activity of therapeutic strategies directed against these tumour-associated 
antigens [17,18]. In a pooled analysis of patients with advanced melanoma 
treated with ipilimumab, an antibody directed against CTLA-4, three-year 
survival was found to range between 20 and 26% [19]. Amongst a cohort of 
107 patients with advanced melanoma, one of the earliest to be treated with 
nivolumab, an anti-PD-1 antibody, 5-year survival was recently reported as 
34% (Hodi S., AACR, 2016). Whilst this is remarkable in a solid tumour 
subtype many deemed ‘untreatable’, it is important to acknowledge that the 
majority of patients do not respond to these forms of immune checkpoint 
blockade, at least as monotherapy. The search for predictive biomarkers in 
this setting has been challenging, however the identification of an inextricable 
relationship between the genomic landscape and anti-tumour immunity has 
served to re-highlight the importance of identifying the most relevant 
substrates for T cell recognition, whilst simultaneously addressing regulation 
at the tumour site.  
 
The search for clinically relevant targets of immune response has shifted 
focus more recently. Tumour-specific mutations may serve as ‘private’ 
neoantigens, eliciting anti-tumour T cell responses [20-23]. In contrast to non-
mutated self antigens, these are thought to be of particular relevance in 
tumour control, since the quality of the T cell pool available for these antigens 
is not affected by central T cell tolerance [24]. Antibody-mediated blockade of 
co-inhibitory immune checkpoint molecules serves to remove the regulation 
limiting the activity of neoantigen-reactive tumour-infiltrating T cells. Patients 
with advanced melanoma and non-small cell lung cancer (NSCLC) deriving 
benefit from CTLA-4 and PD-1 blockade respectively appear to have tumours 
enriched with putative neoantigens [25-27]. The relationship between 
genomics and anti-tumour immunity is, however, complex. Analysis of 110 
patients with advanced melanoma undergoing CTLA-4 blockade 
demonstrated an association between neoantigen burden and clinical benefit, 
however no recurrent neoantigen peptide sequences predicted responder 
patient populations [28]. 
 
Although neoantigens arise from tumour-specific mutations and genetic 
heterogeneity within single tumours is well described, the impact of intra-
tumour heterogeneity (ITH) upon the neoantigen landscape and anti-tumour 
immunity has remained unclear [29-30]. Analysis of 139 patients with 
predominantly early-stage adenocarcinoma of the lung, derived from the The 
Cancer Genome Atlas (TCGA) database, demonstrated that a high burden of 
clonal neoantigens, present in every cancer cell, combined with a low relative 
fraction of subclonal neoantigens (low neoantigen ITH) was associated with 
improved overall survival [31]. The prognostic value of combining these two 
metrics appeared greater than considering either total neoantigen burden or 
neoantigen ITH alone. Importantly, even in the presence of a high burden of 
clonal neoantigens, a high relative fraction of subclonal neoantigens impacted 
negatively on outcome. Analysis of differentially expressed immune-related 
genes between patients with high and low clonal neoantigen burden 
demonstrated that tumours with a high burden of clonal neoantigens 
displayed an inflamed phenotype, with observed high levels of CD8A, IFN-γ, 
GzmB, STAT-1, PD-1, LAG-3 and PD-L1/2 gene expression. In keeping with 
these findings, sensitivity to CTLA-4 and PD-1 blockade in patients with 
advanced melanoma (n=135) and NSCLC (n=31) appeared enhanced in 
tumours enriched for clonal neoantigens. Once again, even in the presence of 
high clonal neoantigen burden, a high relative fraction of subclonal 
neoantigens was observed to impact negatively on response to therapy. 
 
Tumour-specific neoantigens therefore influence anti-tumour immune 
responses. Tumours enriched with clonal neoantigens, shared by all tumour 
cells, display an inflamed phenotype and appear sensitive to immune 
checkpoint blockade, provided they are accompanied by a low relative fraction 
of subclonal neoantigens. The mechanism underlying the negative 
contribution of subclonal neoantigens remains to be elucidated, however 
these findings highlight the importance of determining whether existing 
strategies, including cytotoxic chemotherapy and radiation, induce subclonal 
neoantigens, potentially impacting negatively on immunosurveillance and 
subsequent response to immune checkpoint blockade. Such observations will 
need to be balanced against the potential for the same therapies to have a 
vaccination effect through induction of immunogenic cell death [32]. Adoptive 
transfer of high numbers of effector T cells reactive to clonal neoantigens 
and/or vaccination against multiple clonal neo-epitopes, combined with 
appropriate checkpoint blockade, may serve to overcome the significant 
challenge posed by ITH. Such hypotheses, however, require validation. In an 
era of personalised medicine, these findings serve, at the very least, to help 
better identify those most likely to derive benefit from checkpoint blockade, 
allowing improved patient stratification. Importantly, they also move the 
tumour immunology field a step closer to the ultimate goal of achieving 
durable remissions for the majority, rather than a select few.  
 
         
References  
1.  Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. 
Improved survival with ipilimumab in patients with metastatic melanoma. 
N Engl J Med. 2010 Aug 19;363(8):711–23.  
2.  Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, et al. 
Ipilimumab plus dacarbazine for previously untreated metastatic 
melanoma. N Engl J Med. 2011 Jun 30;364(26):2517–26.  
3.  Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. 
Nivolumab versus chemotherapy in patients with advanced melanoma who 
progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, 
controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375–84.  
4.  Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab 
in previously untreated melanoma without BRAF mutation. N Engl J Med. 
2015 Jan 22;372(4):320–30.  
5.  Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-
programmed-death-receptor-1 treatment with pembrolizumab in 
ipilimumab-refractory advanced melanoma: a randomised dose-
comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20;384(9948):1109–
17.  
6.  Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. 
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-
refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 
trial. Lancet Oncol. 2015 Aug;16(8):908–18.  
7.  Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et 
al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013 
Jul 11;369(2):122–33.  
8.  Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. 
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated 
Melanoma. N Engl J Med. 2015 Jul 2;373(1):23–34.  
9.  Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, 
et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the 
immunotherapy of patients with metastatic melanoma. A preliminary 
report. N Engl J Med. 1988 Dec 22;319(25):1676–80.  
10.  Kawakami Y, Zakut R, Topalian SL, Stötter H, Rosenberg SA. Shared human 
melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-
A2.1-transfected melanomas. J Immunol Baltim Md 1950. 1992 Jan 
15;148(2):638–43.  
11.  Hom SS, Schwartzentruber DJ, Rosenberg SA, Topalian SL. Specific release of 
cytokines by lymphocytes infiltrating human melanomas in response to 
shared melanoma antigens. J Immunother Emphas Tumor Immunol Off J Soc 
Biol Ther. 1993 Jan;13(1):18–30.  
12.  Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den 
Eynde B, et al. A gene encoding an antigen recognized by cytolytic T 
lymphocytes on a human melanoma. Science. 1991 Dec 
13;254(5038):1643–7.  
13.  Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, et al. A 
new gene coding for a differentiation antigen recognized by autologous 
cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994 Jul 
1;180(1):35–42.  
14.  Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, et al. The 
tyrosinase gene codes for an antigen recognized by autologous cytolytic T 
lymphocytes on HLA-A2 melanomas. J Exp Med. 1993 Aug 1;178(2):489–95.  
15.  Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, et 
al. Identification of a human melanoma antigen recognized by tumor-
infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl 
Acad Sci U S A. 1994 Jul 5;91(14):6458–62.  
16.  June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007 
Jun;117(6):1466–76.  
17.  Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. 
A new member of the immunoglobulin superfamily--CTLA-4. Nature. 1987 
Jul 16;328(6127):267–70.  
18.  Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by 
CTLA-4 blockade. Science. 1996 Mar 22;271(5256):1734–6.  
19.  Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. 
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III 
Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 
Off J Am Soc Clin Oncol. 2015 Jun 10;33(17):1889–94.  
20.  Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, et 
al. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008 Feb 
1;68(3):889–92.  
21.  Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, et al. 
Exploiting the mutanome for tumor vaccination. Cancer Res. 2012 Mar 
1;72(5):1081–91.  
22.  Robbins PF, Lu Y-C, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining 
exomic sequencing data to identify mutated antigens recognized by 
adoptively transferred tumor-reactive T cells. Nat Med. 2013 
Jun;19(6):747–52.  
23.  Lu Y-C, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, et al. Mutated PPP1R3B 
is recognized by T cells used to treat a melanoma patient who experienced a 
durable complete tumor regression. J Immunol Baltim Md 1950. 2013 Jun 
15;190(12):6034–42.  
24.  Gilboa E. The makings of a tumor rejection antigen. Immunity. 1999 
Sep;11(3):263–70.  
25.  Van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et 
al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an 
ipilimumab-responsive melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 
2013 Nov 10;31(32):e439–442.  
26.  Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. 
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl 
J Med. 2014 Dec 4;371(23):2189–99.  
27.  Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. 
Cancer immunology. Mutational landscape determines sensitivity to PD-1 
blockade in non-small cell lung cancer. Science. 2015 Apr 3;348(6230):124–
8.  
28.  Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. 
Genomic correlates of response to CTLA-4 blockade in metastatic 
melanoma. Science. 2015 Oct 9;350(6257):207–11.  
29.  Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. 
Intratumor heterogeneity and branched evolution revealed by multiregion 
sequencing. N Engl J Med. 2012 Mar 8;366(10):883–92.  
30.  De Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. 
Spatial and temporal diversity in genomic instability processes defines lung 
cancer evolution. Science. 2014 Oct 10;346(6206):251–6.  
31.  McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et 
al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to 
immune checkpoint blockade. Science [Internet]. 2016 Mar 3 [cited 2016 
Mar 17]; Available from: 
http://www.sciencemag.org/cgi/doi/10.1126/science.aaf1490 
32.  Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, et al. 
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade 
Therapy. Immunity. 2016 Feb 16;44(2):343–54.  
 
 
Financial disclosure/Acknowledgements  
AJSF receives support from the Sam Keen Foundation and UCLH NIHR BRC. 
S.A.Q. is a Cancer Research U.K. (CRUK) Career Development Fellow and is 
funded by a Cancer Research Institute Investigator Award and a CRUK 
Biotherapeutic Program Grant. K.S.P. receives funding from the NIHR BTRU 
for Stem Cells and Immunotherapies, of which he is the Scientific Director. 
